A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants

There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 8; no. 1; pp. 7428 - 12
Main Authors Mathew, James M., H.-Voss, Jessica, LeFever, Ann, Konieczna, Iwona, Stratton, Cheryl, He, Jie, Huang, Xuemei, Gallon, Lorenzo, Skaro, Anton, Ansari, Mohammed Javeed, Leventhal, Joseph R.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 09.05.2018
Nature Publishing Group
Nature Portfolio
Subjects
13/106
13/107
13/21
13/31
631/250/1854/2812
692/308/2779/109/1940
CD19 antigen
CD25 antigen
CD4 antigen
CD8 antigen
Clinical trials
Contamination
Demethylation
Diabetes mellitus
Foxp3 protein
Graft rejection
Hematopoietic stem cells
Humanities and Social Sciences
Hypotheses
Immune response
Immunological tolerance
Immunoregulation
Immunosuppressive agents
Kidney transplantation
Kidney transplants
Lymphocytes T
Morbidity
multidisciplinary
Safety
Science
Science (multidisciplinary)
Side effects
Stem cell transplantation
Stem cells
Transplants & implants
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-018-25574-7

Cover

Abstract There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient’s renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4 + CD25 + with <1% CD8 + and CD19 + contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient’s allo-responders in vitro . Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.
AbstractList There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient’s renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4+CD25+ with <1% CD8+ and CD19+ contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient’s allo-responders in vitro. Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.
There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient's renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4+CD25+ with <1% CD8+ and CD19+ contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient's allo-responders in vitro. Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient's renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4+CD25+ with <1% CD8+ and CD19+ contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient's allo-responders in vitro. Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.
There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient’s renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4 + CD25 + with <1% CD8 + and CD19 + contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient’s allo-responders in vitro . Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.
Abstract There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient’s renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4+CD25+ with <1% CD8+ and CD19+ contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient’s allo-responders in vitro. Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.
There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with juvenile diabetes. Our hypothesis is that infusion(s) of Tregs may induce transplant tolerance thus avoiding long-term use of toxic immunosuppressive agents that cause increased morbidity/mortality. Towards testing our hypothesis, we conducted a phase I dose escalation safety trial infusing billions of ex vivo expanded recipient polyclonal Tregs into living donor kidney transplant recipients. Despite variability in recipient's renal disease, our expansion protocol produced Tregs which met all release criteria, expressing >98% CD4 CD25 with <1% CD8 and CD19 contamination. Our product displayed >80% FOXP3 expression with stable demethylation in the FOXP3 promoter. Functionally, expanded Tregs potently suppressed allogeneic responses and induced the generation of new Tregs in the recipient's allo-responders in vitro. Within recipients, expanded Tregs amplified circulating Treg levels in a sustained manner. Clinically, all doses of Treg therapy tested were safe with no adverse infusion related side effects, infections or rejection events up to two years post-transplant. This study provides the necessary safety data to advance Treg cell therapy to phase II efficacy trials.
ArticleNumber 7428
Author He, Jie
Stratton, Cheryl
Ansari, Mohammed Javeed
LeFever, Ann
Konieczna, Iwona
Huang, Xuemei
H.-Voss, Jessica
Gallon, Lorenzo
Skaro, Anton
Mathew, James M.
Leventhal, Joseph R.
Author_xml – sequence: 1
  givenname: James M.
  orcidid: 0000-0002-5667-750X
  surname: Mathew
  fullname: Mathew, James M.
  email: james-mathew@northwestern.edu
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University
– sequence: 2
  givenname: Jessica
  surname: H.-Voss
  fullname: H.-Voss, Jessica
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University
– sequence: 3
  givenname: Ann
  surname: LeFever
  fullname: LeFever, Ann
  organization: Mathews Center for Cellular Therapy, Northwestern Memorial Hospital
– sequence: 4
  givenname: Iwona
  surname: Konieczna
  fullname: Konieczna, Iwona
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University
– sequence: 5
  givenname: Cheryl
  surname: Stratton
  fullname: Stratton, Cheryl
  organization: Mathews Center for Cellular Therapy, Northwestern Memorial Hospital
– sequence: 6
  givenname: Jie
  surname: He
  fullname: He, Jie
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University
– sequence: 7
  givenname: Xuemei
  surname: Huang
  fullname: Huang, Xuemei
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University
– sequence: 8
  givenname: Lorenzo
  surname: Gallon
  fullname: Gallon, Lorenzo
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Department of Medicine, Division of Nephrology, Feinberg School of Medicine, Northwestern University
– sequence: 9
  givenname: Anton
  surname: Skaro
  fullname: Skaro, Anton
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University
– sequence: 10
  givenname: Mohammed Javeed
  surname: Ansari
  fullname: Ansari, Mohammed Javeed
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Department of Medicine, Division of Nephrology, Feinberg School of Medicine, Northwestern University
– sequence: 11
  givenname: Joseph R.
  surname: Leventhal
  fullname: Leventhal, Joseph R.
  email: jleventh@nm.org
  organization: Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, TRACT Therapeutics
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29743501$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1DAUjFAR_aB_gAOyxIVLwJ-xc0GqlhZWrARCC1fLcZysV157sZOF_nucpoW2h_pgP_nNjMbPc1oc-eBNUbxC8B2CRLxPFLFalBCJEjPGacmfFScYUlZigvHRvfq4OE9pC_NiuKaoflEc45pTwiA6KfwF-LZRyYAlWDjrrVYOrKPN-287bMDlH_DTHkI-98q3pgXfjbZ7a_yQq350agjxGqyBNs4lYD1Y2YP1PfgYfIjgi229ye2ofNo75Yf0snjeKZfM-e15Vvy4ulwvPperr5-Wi4tVqRmFQ9m1ioqaN0J1AiPOGgqpqVmHTKUpzE2jUQURh00NNYcCKUE4o4bX2CCOOTkrlrNuG9RW7qPdqXgtg7Ly5iLEXqo4WO2MxA0kjDHKa4Rog6qGccYhbygRWDS4yVofZq392OxMq_Pjo3IPRB92vN3IPhwkqynBAmaBt7cCMfwaTRrkzqZpYsqbMCaJIeGQVZSSDH3zCLoNY_R5VBOq4hzBCmXU6_uO_lm5-9YMEDNAx5BSNJ3UdlCDDZNB6ySCcgqRnEMkc4jkTYjkNDn8iHqn_iSJzKSUwb438b_tJ1h_ATgi1mw
CitedBy_id crossref_primary_10_1016_j_kint_2023_09_021
crossref_primary_10_1097_MOT_0000000000000670
crossref_primary_10_1038_s41401_021_00641_4
crossref_primary_10_1016_j_autrev_2021_102761
crossref_primary_10_1016_j_hbpd_2024_03_001
crossref_primary_10_1111_xen_12640
crossref_primary_10_3389_fcell_2021_695015
crossref_primary_10_1111_trf_16797
crossref_primary_10_3389_fcvm_2021_812702
crossref_primary_10_3389_fcimb_2024_1342354
crossref_primary_10_1002_cti2_1099
crossref_primary_10_4155_bio_2020_0080
crossref_primary_10_1097_CRD_0000000000000437
crossref_primary_10_3389_fimmu_2022_861607
crossref_primary_10_1016_j_ymthe_2020_05_023
crossref_primary_10_1111_ajt_16395
crossref_primary_10_1111_ajt_16393
crossref_primary_10_1016_j_tibtech_2019_12_009
crossref_primary_10_1016_j_cellimm_2020_104193
crossref_primary_10_3389_fimmu_2019_00181
crossref_primary_10_1172_JCI170505
crossref_primary_10_1097_TP_0000000000002711
crossref_primary_10_1097_FTD_0000000000001275
crossref_primary_10_3389_fimmu_2020_01326
crossref_primary_10_57603_EJT_010
crossref_primary_10_1182_bloodadvances_2021004453C
crossref_primary_10_4049_immunohorizons_2100021
crossref_primary_10_1002_eji_202149387
crossref_primary_10_1016_j_jcyt_2022_06_006
crossref_primary_10_1177_09636897211046556
crossref_primary_10_1016_j_trre_2023_100792
crossref_primary_10_3389_fimmu_2024_1372862
crossref_primary_10_1177_0963689720923578
crossref_primary_10_1016_j_eng_2021_03_029
crossref_primary_10_1016_j_eng_2021_10_018
crossref_primary_10_1182_bloodadvances_2019000411
crossref_primary_10_1016_j_clim_2023_109716
crossref_primary_10_1016_j_cellimm_2020_104236
crossref_primary_10_3389_fimmu_2022_1055466
crossref_primary_10_1186_s12974_022_02395_0
crossref_primary_10_3389_fimmu_2023_1235889
crossref_primary_10_1016_j_ajt_2023_06_012
crossref_primary_10_1016_j_jhepr_2025_101394
crossref_primary_10_1111_ajt_16139
crossref_primary_10_3390_ijms24021752
crossref_primary_10_1097_TP_0000000000004866
crossref_primary_10_1111_cei_13537
crossref_primary_10_1097_TP_0000000000005311
crossref_primary_10_3389_fimmu_2020_02005
crossref_primary_10_3389_fimmu_2021_664244
crossref_primary_10_1016_j_actbio_2024_02_002
crossref_primary_10_1016_j_clim_2023_109328
crossref_primary_10_1016_j_isci_2021_102842
crossref_primary_10_3389_fimmu_2021_686439
crossref_primary_10_1126_scitranslmed_abf5264
crossref_primary_10_3389_fcell_2022_1081644
crossref_primary_10_1016_j_jaut_2019_102376
crossref_primary_10_1111_ajt_16095
crossref_primary_10_1080_08923973_2021_1891247
crossref_primary_10_1210_endrev_bnaa028
crossref_primary_10_1093_cei_uxac118
crossref_primary_10_3389_fimmu_2022_849939
crossref_primary_10_1111_ajt_15680
crossref_primary_10_3390_ijms22147536
crossref_primary_10_1089_hum_2023_227
crossref_primary_10_1002_eji_202250007
crossref_primary_10_3390_ijms22189676
crossref_primary_10_1016_j_ajt_2023_04_017
crossref_primary_10_1080_15476278_2022_2164159
crossref_primary_10_1016_j_molmed_2021_03_005
crossref_primary_10_3389_fmed_2023_1090721
crossref_primary_10_1016_j_trim_2021_101518
crossref_primary_10_1136_gutjnl_2019_319850
crossref_primary_10_1016_j_ajt_2024_10_024
crossref_primary_10_3390_ijms21072356
crossref_primary_10_3389_fimmu_2021_744763
crossref_primary_10_1053_j_ajkd_2020_07_006
crossref_primary_10_1172_jci_insight_167457
crossref_primary_10_3389_fimmu_2019_00889
crossref_primary_10_1016_j_jcyt_2022_01_001
crossref_primary_10_3389_ti_2024_13485
crossref_primary_10_3389_fimmu_2020_565518
crossref_primary_10_1097_MNH_0000000000000737
crossref_primary_10_3389_fimmu_2021_631365
crossref_primary_10_1111_cei_13482
crossref_primary_10_1016_j_jaci_2018_10_015
crossref_primary_10_1111_tri_13972
crossref_primary_10_1016_j_cellimm_2020_104214
crossref_primary_10_3389_fimmu_2022_1017683
crossref_primary_10_1111_sji_13212
crossref_primary_10_3389_fimmu_2022_926648
crossref_primary_10_1016_j_autrev_2022_103257
crossref_primary_10_1111_ajt_15700
crossref_primary_10_1016_j_tsep_2024_103022
crossref_primary_10_1111_ajt_15306
crossref_primary_10_3389_fimmu_2019_00274
crossref_primary_10_3389_fimmu_2025_1516772
crossref_primary_10_3389_fimmu_2021_686530
crossref_primary_10_1111_ajt_17209
crossref_primary_10_1172_jci_insight_152213
crossref_primary_10_1016_j_trim_2019_101259
crossref_primary_10_3389_fimmu_2021_717594
crossref_primary_10_1002_mco2_669
crossref_primary_10_1016_j_jcyt_2019_10_011
crossref_primary_10_1111_ajt_16740
crossref_primary_10_1016_j_trim_2021_101411
crossref_primary_10_1097_TP_0000000000004814
crossref_primary_10_12677_ACM_2022_124413
crossref_primary_10_1016_j_it_2019_11_005
crossref_primary_10_1016_j_ekir_2022_03_030
crossref_primary_10_1097_TP_0000000000005064
crossref_primary_10_1097_TP_0000000000005065
crossref_primary_10_1182_blood_2021012249
crossref_primary_10_34067_KID_0005692020
crossref_primary_10_1038_s41598_018_37218_x
crossref_primary_10_1111_imr_12812
crossref_primary_10_3389_fped_2022_862807
crossref_primary_10_1016_S0140_6736_20_30803_5
crossref_primary_10_1038_s41598_022_11290_w
crossref_primary_10_1007_s12016_021_08866_1
crossref_primary_10_1016_j_addr_2023_115161
crossref_primary_10_3389_fbioe_2022_942750
crossref_primary_10_3389_fimmu_2024_1509956
crossref_primary_10_1016_j_intimp_2020_107195
crossref_primary_10_1038_s41581_023_00733_w
crossref_primary_10_1186_s41231_023_00150_y
crossref_primary_10_1007_s00467_024_06514_2
crossref_primary_10_3389_fimmu_2019_03047
crossref_primary_10_17235_reed_2022_9010_2022
crossref_primary_10_1007_s00467_021_05023_w
crossref_primary_10_1186_s13287_019_1397_4
crossref_primary_10_3390_cancers15245877
crossref_primary_10_1016_j_bj_2022_01_005
crossref_primary_10_1111_tri_13789
crossref_primary_10_1007_s00005_020_00582_6
crossref_primary_10_1016_S0140_6736_20_30167_7
crossref_primary_10_1111_imr_12801
crossref_primary_10_1111_tan_14591
crossref_primary_10_3389_fimmu_2020_585819
crossref_primary_10_1016_j_jtcvs_2019_01_101
crossref_primary_10_1002_adhm_202202238
crossref_primary_10_3389_fimmu_2023_1166135
crossref_primary_10_1111_tri_13780
crossref_primary_10_3389_fimmu_2022_883855
crossref_primary_10_1002_eji_202048746
crossref_primary_10_1111_cei_13297
crossref_primary_10_3389_fphar_2020_588436
crossref_primary_10_1111_cei_13288
crossref_primary_10_1016_j_jss_2023_04_028
crossref_primary_10_1016_j_biotechadv_2019_107455
crossref_primary_10_1007_s40472_020_00278_y
crossref_primary_10_1002_cbf_3852
crossref_primary_10_1111_ajt_16842
crossref_primary_10_1172_jci_insight_126194
crossref_primary_10_1097_TP_0000000000004316
crossref_primary_10_3389_fimmu_2021_641596
crossref_primary_10_1136_bmj_m3734
crossref_primary_10_3389_fimmu_2019_00043
crossref_primary_10_1016_j_jaut_2022_102986
crossref_primary_10_1111_all_14478
crossref_primary_10_3390_pathogens9080607
crossref_primary_10_4236_ojneph_2021_113035
crossref_primary_10_3389_fimmu_2022_746889
crossref_primary_10_1016_j_it_2021_11_001
crossref_primary_10_1016_j_xcrm_2022_100614
crossref_primary_10_1007_s40620_024_01888_w
crossref_primary_10_4049_jimmunol_2300289
crossref_primary_10_1097_TP_0000000000003617
crossref_primary_10_1002_cyto_b_21841
Cites_doi 10.1126/scitranslmed.aad4134
10.1097/TP.0b013e31827d62e3
10.1111/ajt.13416
10.1056/NEJM199408113310606
10.1111/j.1600-6143.2012.04013.x
10.1084/jem.20110767
10.1097/01.tp.0000250731.44913.ee
10.4049/jimmunol.1401250
10.1084/jem.20012097
10.1056/NEJM198801283180406
10.1038/leu.2014.180
10.1016/j.immuni.2008.12.022
10.1126/scitranslmed.3003509
10.1111/j.1600-6143.2007.02088.x
10.1097/TP.0b013e3181bbee98
10.1016/j.immuni.2012.09.010
10.1038/s41598-018-19621-6
10.2165/00003495-199244040-00003
10.1056/NEJM199806113382407
10.1371/journal.pone.0148474
10.1056/NEJM200003023420901
10.4049/jimmunol.168.11.5558
10.1016/j.clim.2009.06.001
10.1182/blood-2010-07-293795
10.1111/imm.12351
10.1016/j.bbmt.2010.12.710
10.1055/s-0029-1192058
10.1080/2162402X.2016.1146842
10.1016/S0039-6109(05)70637-X
10.1111/j.1600-6143.2011.03961.x
10.1097/TP.0000000000000717
10.1097/TP.0000000000000869
10.1097/00007890-200012270-00003
10.1002/hep.28459
10.1053/ajkd.2001.28923
10.1002/eji.201040509
10.1038/nri2785
10.4049/jimmunol.166.6.3789
10.1111/ajt.14415
10.1097/MOT.0b013e328355a992
10.1084/jem.20041709
10.1097/00007890-199704150-00013
10.1097/TP.0b013e318200e97
10.1111/ajt.13132
10.1182/blood-2010-10-311894
10.1016/S0041-1345(01)01960-1
10.1681/ASN.V212s238
10.1002/0470871628.ch13
10.1093/clinchem/42.8.1316
10.1681/ASN.V48s2
10.1097/TP.1090b1013e31829f31607
10.1016/j.humimm.2017.12.010
ContentType Journal Article
Copyright The Author(s) 2018
2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2018
– notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-018-25574-7
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic
CrossRef



PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 12
ExternalDocumentID oai_doaj_org_article_2b03555479114b16b575707b43828b2b
PMC5943280
29743501
10_1038_s41598_018_25574_7
Genre Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IPNFZ
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c540t-fda4897b8af82175b404e95f1e6c40da4ec160170b90c7081a83754e792e17273
IEDL.DBID 7X7
ISSN 2045-2322
IngestDate Wed Aug 27 01:27:11 EDT 2025
Thu Aug 21 18:32:05 EDT 2025
Thu Sep 04 16:39:37 EDT 2025
Wed Aug 13 04:43:41 EDT 2025
Wed Feb 19 02:44:35 EST 2025
Thu Apr 24 22:59:50 EDT 2025
Tue Jul 01 02:51:02 EDT 2025
Fri Feb 21 02:38:11 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-fda4897b8af82175b404e95f1e6c40da4ec160170b90c7081a83754e792e17273
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5667-750X
OpenAccessLink https://www.proquest.com/docview/2036771061?pq-origsite=%requestingapplication%
PMID 29743501
PQID 2036771061
PQPubID 2041939
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_2b03555479114b16b575707b43828b2b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5943280
proquest_miscellaneous_2037056443
proquest_journals_2036771061
pubmed_primary_29743501
crossref_citationtrail_10_1038_s41598_018_25574_7
crossref_primary_10_1038_s41598_018_25574_7
springer_journals_10_1038_s41598_018_25574_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-05-09
PublicationDateYYYYMMDD 2018-05-09
PublicationDate_xml – month: 05
  year: 2018
  text: 2018-05-09
  day: 09
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2018
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Knechtle, Kwun (CR47) 2009; 29
Sawitzki (CR31) 2001; 33
Sakaguchi, Miyara, Costantino, Hafler (CR39) 2010; 10
Gaston (CR6) 2001; 38
Mathew (CR56) 2000; 70
Shaw, Kaplan, Kaufman (CR8) 1996; 42
Gallon (CR27) 2015; 99
Pirsch, Miller, Deierhoi, Vincenti, Filo (CR13) 1997; 63
Lee (CR32) 2005; 201
Semple, Yu, Wang, Anasetti, Yu (CR20) 2011; 17
Brunstein (CR22) 2011; 117
O’Leary (CR53) 2016; 100
Heinrichs (CR18) 2016; 5
Leventhal (CR25) 2012; 4
Boubenider (CR9) 1997; 10
Peccatori (CR29) 2015; 29
Xia, He, Zhang, Leventhal (CR16) 2006; 82
Mathew (CR44) 2018; 8
CR46
Sia, Paya (CR12) 1998; 78
Kim, Chung, Kim, Cho, Yang (CR28) 2015; 144
Francis (CR35) 2011; 41
Ohkura (CR38) 2012; 37
Gershon, Kondo (CR36) 1971; 21
Bluestone (CR24) 2015; 7
Kendal (CR42) 2011; 208
Heinrichs (CR17) 2016; 1
Graca, Cobbold, Waldmann (CR34) 2002; 195
Levitsky (CR37) 2009; 88
Schmidt, Eriksson, Shang, Weyd, Tegner (CR30) 2016; 11
Barry (CR3) 1992; 44
DeMario, Liebowitz (CR11) 1998; 25
Xia, He, Leventhal (CR15) 2008; 8
CR14
CR57
Tang, Lee (CR43) 2012; 17
Li (CR19) 2015; 195
Leventhal (CR54) 2015; 15
Zhang (CR33) 2009; 30
Rostaing (CR51) 2015; 15
Leventhal (CR55) 2016; 16
Di Ianni (CR23) 2011; 117
Eggers (CR1) 1988; 318
Levitsky (CR26) 2011; 91
Chandran (CR48) 2017; 17
Hariharan (CR2) 2000; 342
Wiebe (CR49) 2012; 12
Todo (CR45) 2016; 64
Graca (CR41) 2002; 168
Helderman, Van Buren, Amend, Pirsch (CR5) 1994; 4
Trzonkowski (CR21) 2009; 133
Hara (CR40) 2001; 166
Liefeldt (CR52) 2012; 12
Fishman, Rubin (CR10) 1998; 338
Suthanthiran, Strom (CR4) 1994; 331
Pirsch (CR7) 1992; 2
Everly (CR50) 2013; 95
J Heinrichs (25574_CR17) 2016; 1
S Hariharan (25574_CR2) 2000; 342
MD DeMario (25574_CR11) 1998; 25
L Rostaing (25574_CR51) 2015; 15
M Suthanthiran (25574_CR4) 1994; 331
JM Barry (25574_CR3) 1992; 44
S Sakaguchi (25574_CR39) 2010; 10
JM Mathew (25574_CR44) 2018; 8
JG O’Leary (25574_CR53) 2016; 100
JR Leventhal (25574_CR54) 2015; 15
L Liefeldt (25574_CR52) 2012; 12
K Semple (25574_CR20) 2011; 17
LM Shaw (25574_CR8) 1996; 42
RS Gaston (25574_CR6) 2001; 38
J Peccatori (25574_CR29) 2015; 29
J Leventhal (25574_CR25) 2012; 4
I Lee (25574_CR32) 2005; 201
N Ohkura (25574_CR38) 2012; 37
N Zhang (25574_CR33) 2009; 30
J Levitsky (25574_CR26) 2011; 91
B Sawitzki (25574_CR31) 2001; 33
A Schmidt (25574_CR30) 2016; 11
L Gallon (25574_CR27) 2015; 99
G Xia (25574_CR16) 2006; 82
J Heinrichs (25574_CR18) 2016; 5
KW Kim (25574_CR28) 2015; 144
M Hara (25574_CR40) 2001; 166
M Di Ianni (25574_CR23) 2011; 117
L Graca (25574_CR41) 2002; 168
CG Brunstein (25574_CR22) 2011; 117
J Levitsky (25574_CR37) 2009; 88
PW Eggers (25574_CR1) 1988; 318
Q Tang (25574_CR43) 2012; 17
L Graca (25574_CR34) 2002; 195
JA Bluestone (25574_CR24) 2015; 7
JM Mathew (25574_CR56) 2000; 70
MJ Everly (25574_CR50) 2013; 95
25574_CR14
JD Pirsch (25574_CR7) 1992; 2
25574_CR57
RS Francis (25574_CR35) 2011; 41
G Xia (25574_CR15) 2008; 8
P Trzonkowski (25574_CR21) 2009; 133
S Chandran (25574_CR48) 2017; 17
JA Fishman (25574_CR10) 1998; 338
RK Gershon (25574_CR36) 1971; 21
C Wiebe (25574_CR49) 2012; 12
AR Kendal (25574_CR42) 2011; 208
JR Leventhal (25574_CR55) 2016; 16
JH Helderman (25574_CR5) 1994; 4
25574_CR46
J Li (25574_CR19) 2015; 195
JD Pirsch (25574_CR13) 1997; 63
S Todo (25574_CR45) 2016; 64
S Boubenider (25574_CR9) 1997; 10
SJ Knechtle (25574_CR47) 2009; 29
IG Sia (25574_CR12) 1998; 78
References_xml – volume: 7
  start-page: 315ra189
  year: 2015
  ident: CR24
  article-title: Type 1 diabetes immunotherapy using polyclonal regulatory T cells
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aad4134
– volume: 95
  start-page: 410
  year: 2013
  end-page: 417
  ident: CR50
  article-title: Incidence and impact of de novo donor-specific alloantibody in primary renal allografts
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e31827d62e3
– volume: 16
  start-page: 221
  year: 2016
  end-page: 234
  ident: CR55
  article-title: Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers
  publication-title: Am J Transplant
  doi: 10.1111/ajt.13416
– volume: 331
  start-page: 365
  year: 1994
  end-page: 376
  ident: CR4
  article-title: Renal transplantation
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199408113310606
– volume: 12
  start-page: 1157
  year: 2012
  end-page: 1167
  ident: CR49
  article-title: Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2012.04013.x
– volume: 208
  start-page: 2043
  year: 2011
  end-page: 2053
  ident: CR42
  article-title: Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance
  publication-title: J Exp Med
  doi: 10.1084/jem.20110767
– volume: 82
  start-page: 1749
  year: 2006
  end-page: 1755
  ident: CR16
  article-title: Targeting acute allograft rejection by immunotherapy with -expanded natural CD4+ CD25+ regulatory T cells
  publication-title: Transplantation
  doi: 10.1097/01.tp.0000250731.44913.ee
– volume: 195
  start-page: 717
  year: 2015
  end-page: 725
  ident: CR19
  article-title: HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1401250
– volume: 195
  start-page: 1641
  year: 2002
  end-page: 1646
  ident: CR34
  article-title: Identification of regulatory T cells in tolerated allografts
  publication-title: J Exp Med
  doi: 10.1084/jem.20012097
– volume: 318
  start-page: 223
  year: 1988
  end-page: 229
  ident: CR1
  article-title: Effect of transplantation on the Medicare end-stage renal disease program
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198801283180406
– volume: 29
  start-page: 396
  year: 2015
  end-page: 405
  ident: CR29
  article-title: Sirolimus-based graft-versus-host disease prophylaxis promotes the expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
  publication-title: Leukemia
  doi: 10.1038/leu.2014.180
– volume: 42
  start-page: 1316
  year: 1996
  end-page: 1321
  ident: CR8
  article-title: Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them
  publication-title: Clin Chem
– volume: 30
  start-page: 458
  year: 2009
  end-page: 469
  ident: CR33
  article-title: Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response
  publication-title: Immunity
  doi: 10.1016/j.immuni.2008.12.022
– volume: 4
  start-page: 124ra128
  year: 2012
  ident: CR25
  article-title: Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3003509
– volume: 4
  start-page: S2
  year: 1994
  end-page: 9
  ident: CR5
  article-title: Chronic immunosuppression of the renal transplant patient
  publication-title: J Am Soc Nephrol
– ident: CR46
– volume: 8
  start-page: 298
  year: 2008
  end-page: 306
  ident: CR15
  article-title: -expanded natural CD4+ CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2007.02088.x
– volume: 88
  start-page: 1303
  year: 2009
  end-page: 1311
  ident: CR37
  article-title: The human “Treg MLR”: immune monitoring for FOXP3+ T regulatory cell generation
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e3181bbee98
– volume: 37
  start-page: 785
  year: 2012
  end-page: 799
  ident: CR38
  article-title: T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development
  publication-title: Immunity
  doi: 10.1016/j.immuni.2012.09.010
– volume: 8
  year: 2018
  ident: CR44
  article-title: Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance
  publication-title: Scientific Reports
  doi: 10.1038/s41598-018-19621-6
– volume: 44
  start-page: 554
  year: 1992
  end-page: 566
  ident: CR3
  article-title: Immunosuppressive drugs in renal transplantation. A review of the regimens
  publication-title: Drugs
  doi: 10.2165/00003495-199244040-00003
– volume: 338
  start-page: 1741
  year: 1998
  end-page: 1751
  ident: CR10
  article-title: Infection in organ-transplant recipients
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199806113382407
– volume: 25
  start-page: 492
  year: 1998
  end-page: 502
  ident: CR11
  article-title: Lymphomas in the immunocompromised patient
  publication-title: Semin Oncol
– volume: 11
  start-page: e0148474
  year: 2016
  ident: CR30
  article-title: Comparative Analysis of Protocols to Induce Human CD4+ Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate
  publication-title: PLoS ONE [Electronic Resource]
  doi: 10.1371/journal.pone.0148474
– volume: 342
  start-page: 605
  year: 2000
  end-page: 612
  ident: CR2
  article-title: Improved graft survival after renal transplantation in the United States, 1988 to 1996
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200003023420901
– volume: 1
  start-page: 1
  year: 2016
  end-page: 14
  ident: CR17
  article-title: Regulatory T-Cell Therapy for Graft-versus-host Disease
  publication-title: J Immunol Res Ther
– ident: CR57
– volume: 168
  start-page: 5558
  year: 2002
  end-page: 5565
  ident: CR41
  article-title: Both CD4(+)CD25(+) and CD4(+)CD25(−) regulatory cells mediate dominant transplantation tolerance
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.11.5558
– volume: 133
  start-page: 22
  year: 2009
  end-page: 26
  ident: CR21
  article-title: First-in-man clinical results of the treatment of patients with graft versus host disease with human expanded CD4+ CD25+ CD127− T regulatory cells
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2009.06.001
– volume: 117
  start-page: 1061
  year: 2011
  end-page: 1070
  ident: CR22
  article-title: Infusion of expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
  publication-title: Blood
  doi: 10.1182/blood-2010-07-293795
– volume: 144
  start-page: 68
  year: 2015
  end-page: 78
  ident: CR28
  article-title: The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation and in kidney transplant recipients
  publication-title: Immunology
  doi: 10.1111/imm.12351
– volume: 17
  start-page: 309
  year: 2011
  end-page: 318
  ident: CR20
  article-title: Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.12.710
– volume: 29
  start-page: 91
  year: 2009
  end-page: 101
  ident: CR47
  article-title: Unique aspects of rejection and tolerance in liver transplantation
  publication-title: Semin Liver Dis
  doi: 10.1055/s-0029-1192058
– ident: CR14
– volume: 5
  start-page: e1146842
  year: 2016
  ident: CR18
  article-title: CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1146842
– volume: 78
  start-page: 95
  year: 1998
  end-page: 112
  ident: CR12
  article-title: Infectious complications following renal transplantation
  publication-title: Surg Clin North Am
  doi: 10.1016/S0039-6109(05)70637-X
– volume: 15
  start-page: 3031
  year: 2015
  ident: CR54
  article-title: Interim Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Living Donor Kidney Transplant Recipients
  publication-title: Am J Transplant
– volume: 12
  start-page: 1192
  year: 2012
  end-page: 1198
  ident: CR52
  article-title: Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2011.03961.x
– volume: 99
  start-page: 1774
  year: 2015
  end-page: 1784
  ident: CR27
  article-title: Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000717
– volume: 100
  start-page: 39
  year: 2016
  end-page: 53
  ident: CR53
  article-title: The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000869
– volume: 70
  start-page: 1675
  year: 2000
  end-page: 1682
  ident: CR56
  article-title: Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses
  publication-title: Transplantation
  doi: 10.1097/00007890-200012270-00003
– volume: 64
  start-page: 632
  year: 2016
  end-page: 643
  ident: CR45
  article-title: A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation
  publication-title: Hepatology
  doi: 10.1002/hep.28459
– volume: 38
  start-page: S25
  year: 2001
  end-page: 35
  ident: CR6
  article-title: Maintenance immunosuppression in the renal transplant recipient: an overview
  publication-title: Am J Kidney Dis
  doi: 10.1053/ajkd.2001.28923
– volume: 41
  start-page: 726
  year: 2011
  end-page: 738
  ident: CR35
  article-title: Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201040509
– volume: 21
  start-page: 903
  year: 1971
  end-page: 914
  ident: CR36
  article-title: Infectious immunological tolerance
  publication-title: Immunology
– volume: 2
  start-page: S238
  year: 1992
  end-page: 242
  ident: CR7
  article-title: Hyperlipidemia and transplantation: etiologic factors and therapy
  publication-title: J Am Soc Nephrol
– volume: 10
  start-page: 490
  year: 2010
  end-page: 500
  ident: CR39
  article-title: FOXP3+ regulatory T cells in the human immune system
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2785
– volume: 166
  start-page: 3789
  year: 2001
  end-page: 3796
  ident: CR40
  article-title: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens
  publication-title: J Immunol
  doi: 10.4049/jimmunol.166.6.3789
– volume: 17
  start-page: 2945
  year: 2017
  end-page: 2954
  ident: CR48
  article-title: Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants
  publication-title: Am J Transplant
  doi: 10.1111/ajt.14415
– volume: 17
  start-page: 349
  year: 2012
  end-page: 354
  ident: CR43
  article-title: Regulatory T-cell therapy for transplantation: how many cells do we need?
  publication-title: Curr Opin Organ Transplant
  doi: 10.1097/MOT.0b013e328355a992
– volume: 201
  start-page: 1037
  year: 2005
  end-page: 1044
  ident: CR32
  article-title: Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor
  publication-title: J Exp Med
  doi: 10.1084/jem.20041709
– volume: 63
  start-page: 977
  year: 1997
  end-page: 983
  ident: CR13
  article-title: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
  publication-title: Transplantation
  doi: 10.1097/00007890-199704150-00013
– volume: 91
  start-page: 199
  year: 2011
  end-page: 206
  ident: CR26
  article-title: Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e318200e97
– volume: 15
  start-page: 1303
  year: 2015
  end-page: 1312
  ident: CR51
  article-title: Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA
  publication-title: Am J Transplant
  doi: 10.1111/ajt.13132
– volume: 117
  start-page: 3921
  year: 2011
  end-page: 3928
  ident: CR23
  article-title: Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
  publication-title: Blood
  doi: 10.1182/blood-2010-10-311894
– volume: 33
  start-page: 2092
  year: 2001
  end-page: 2093
  ident: CR31
  article-title: Regulatory tolerance-mediating T cells in transplantation tolerance
  publication-title: Transplant Proc
  doi: 10.1016/S0041-1345(01)01960-1
– volume: 10
  start-page: 136
  year: 1997
  end-page: 145
  ident: CR9
  article-title: Incidence and consequences of post-transplantation lymphoproliferative disorders
  publication-title: J Nephrol
– volume: 8
  year: 2018
  ident: 25574_CR44
  publication-title: Scientific Reports
  doi: 10.1038/s41598-018-19621-6
– volume: 44
  start-page: 554
  year: 1992
  ident: 25574_CR3
  publication-title: Drugs
  doi: 10.2165/00003495-199244040-00003
– volume: 15
  start-page: 3031
  year: 2015
  ident: 25574_CR54
  publication-title: Am J Transplant
– volume: 37
  start-page: 785
  year: 2012
  ident: 25574_CR38
  publication-title: Immunity
  doi: 10.1016/j.immuni.2012.09.010
– volume: 30
  start-page: 458
  year: 2009
  ident: 25574_CR33
  publication-title: Immunity
  doi: 10.1016/j.immuni.2008.12.022
– volume: 117
  start-page: 3921
  year: 2011
  ident: 25574_CR23
  publication-title: Blood
  doi: 10.1182/blood-2010-10-311894
– volume: 1
  start-page: 1
  year: 2016
  ident: 25574_CR17
  publication-title: J Immunol Res Ther
– volume: 21
  start-page: 903
  year: 1971
  ident: 25574_CR36
  publication-title: Immunology
– volume: 33
  start-page: 2092
  year: 2001
  ident: 25574_CR31
  publication-title: Transplant Proc
  doi: 10.1016/S0041-1345(01)01960-1
– volume: 88
  start-page: 1303
  year: 2009
  ident: 25574_CR37
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e3181bbee98
– volume: 2
  start-page: S238
  year: 1992
  ident: 25574_CR7
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V212s238
– volume: 168
  start-page: 5558
  year: 2002
  ident: 25574_CR41
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.11.5558
– volume: 133
  start-page: 22
  year: 2009
  ident: 25574_CR21
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2009.06.001
– volume: 144
  start-page: 68
  year: 2015
  ident: 25574_CR28
  publication-title: Immunology
  doi: 10.1111/imm.12351
– volume: 16
  start-page: 221
  year: 2016
  ident: 25574_CR55
  publication-title: Am J Transplant
  doi: 10.1111/ajt.13416
– volume: 342
  start-page: 605
  year: 2000
  ident: 25574_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200003023420901
– volume: 29
  start-page: 91
  year: 2009
  ident: 25574_CR47
  publication-title: Semin Liver Dis
  doi: 10.1055/s-0029-1192058
– volume: 318
  start-page: 223
  year: 1988
  ident: 25574_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198801283180406
– volume: 195
  start-page: 1641
  year: 2002
  ident: 25574_CR34
  publication-title: J Exp Med
  doi: 10.1084/jem.20012097
– volume: 117
  start-page: 1061
  year: 2011
  ident: 25574_CR22
  publication-title: Blood
  doi: 10.1182/blood-2010-07-293795
– volume: 70
  start-page: 1675
  year: 2000
  ident: 25574_CR56
  publication-title: Transplantation
  doi: 10.1097/00007890-200012270-00003
– volume: 166
  start-page: 3789
  year: 2001
  ident: 25574_CR40
  publication-title: J Immunol
  doi: 10.4049/jimmunol.166.6.3789
– volume: 95
  start-page: 410
  year: 2013
  ident: 25574_CR50
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e31827d62e3
– volume: 38
  start-page: S25
  year: 2001
  ident: 25574_CR6
  publication-title: Am J Kidney Dis
  doi: 10.1053/ajkd.2001.28923
– ident: 25574_CR14
  doi: 10.1002/0470871628.ch13
– volume: 10
  start-page: 490
  year: 2010
  ident: 25574_CR39
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2785
– volume: 42
  start-page: 1316
  year: 1996
  ident: 25574_CR8
  publication-title: Clin Chem
  doi: 10.1093/clinchem/42.8.1316
– volume: 17
  start-page: 2945
  year: 2017
  ident: 25574_CR48
  publication-title: Am J Transplant
  doi: 10.1111/ajt.14415
– volume: 91
  start-page: 199
  year: 2011
  ident: 25574_CR26
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e318200e97
– volume: 15
  start-page: 1303
  year: 2015
  ident: 25574_CR51
  publication-title: Am J Transplant
  doi: 10.1111/ajt.13132
– volume: 4
  start-page: 124ra128
  year: 2012
  ident: 25574_CR25
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3003509
– volume: 12
  start-page: 1192
  year: 2012
  ident: 25574_CR52
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2011.03961.x
– volume: 17
  start-page: 309
  year: 2011
  ident: 25574_CR20
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.12.710
– volume: 5
  start-page: e1146842
  year: 2016
  ident: 25574_CR18
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1146842
– volume: 4
  start-page: S2
  year: 1994
  ident: 25574_CR5
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V48s2
– volume: 78
  start-page: 95
  year: 1998
  ident: 25574_CR12
  publication-title: Surg Clin North Am
  doi: 10.1016/S0039-6109(05)70637-X
– volume: 64
  start-page: 632
  year: 2016
  ident: 25574_CR45
  publication-title: Hepatology
  doi: 10.1002/hep.28459
– volume: 195
  start-page: 717
  year: 2015
  ident: 25574_CR19
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1401250
– volume: 10
  start-page: 136
  year: 1997
  ident: 25574_CR9
  publication-title: J Nephrol
– volume: 338
  start-page: 1741
  year: 1998
  ident: 25574_CR10
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199806113382407
– volume: 8
  start-page: 298
  year: 2008
  ident: 25574_CR15
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2007.02088.x
– ident: 25574_CR57
  doi: 10.1097/TP.1090b1013e31829f31607
– volume: 25
  start-page: 492
  year: 1998
  ident: 25574_CR11
  publication-title: Semin Oncol
– volume: 201
  start-page: 1037
  year: 2005
  ident: 25574_CR32
  publication-title: J Exp Med
  doi: 10.1084/jem.20041709
– volume: 12
  start-page: 1157
  year: 2012
  ident: 25574_CR49
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2012.04013.x
– ident: 25574_CR46
  doi: 10.1016/j.humimm.2017.12.010
– volume: 82
  start-page: 1749
  year: 2006
  ident: 25574_CR16
  publication-title: Transplantation
  doi: 10.1097/01.tp.0000250731.44913.ee
– volume: 41
  start-page: 726
  year: 2011
  ident: 25574_CR35
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201040509
– volume: 208
  start-page: 2043
  year: 2011
  ident: 25574_CR42
  publication-title: J Exp Med
  doi: 10.1084/jem.20110767
– volume: 7
  start-page: 315ra189
  year: 2015
  ident: 25574_CR24
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aad4134
– volume: 17
  start-page: 349
  year: 2012
  ident: 25574_CR43
  publication-title: Curr Opin Organ Transplant
  doi: 10.1097/MOT.0b013e328355a992
– volume: 29
  start-page: 396
  year: 2015
  ident: 25574_CR29
  publication-title: Leukemia
  doi: 10.1038/leu.2014.180
– volume: 11
  start-page: e0148474
  year: 2016
  ident: 25574_CR30
  publication-title: PLoS ONE [Electronic Resource]
  doi: 10.1371/journal.pone.0148474
– volume: 331
  start-page: 365
  year: 1994
  ident: 25574_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199408113310606
– volume: 63
  start-page: 977
  year: 1997
  ident: 25574_CR13
  publication-title: Transplantation
  doi: 10.1097/00007890-199704150-00013
– volume: 100
  start-page: 39
  year: 2016
  ident: 25574_CR53
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000869
– volume: 99
  start-page: 1774
  year: 2015
  ident: 25574_CR27
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000717
SSID ssj0000529419
Score 2.601273
Snippet There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have...
Abstract There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 7428
SubjectTerms 13/106
13/107
13/21
13/31
631/250/1854/2812
692/308/2779/109/1940
CD19 antigen
CD25 antigen
CD4 antigen
CD8 antigen
Clinical trials
Contamination
Demethylation
Diabetes mellitus
Foxp3 protein
Graft rejection
Hematopoietic stem cells
Humanities and Social Sciences
Hypotheses
Immune response
Immunological tolerance
Immunoregulation
Immunosuppressive agents
Kidney transplantation
Kidney transplants
Lymphocytes T
Morbidity
multidisciplinary
Safety
Science
Science (multidisciplinary)
Side effects
Stem cell transplantation
Stem cells
Transplants & implants
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqSki9IB5tCRTkSr1BVMdrx_axQKvSFsRhW_VmxY6jRlo5q90tov-eGSe7dIHChVNWsSNZ89j57Bl_Q8iB54EZV9e5UNLnEPFlro0r8xpiZ9HUYsQTffHnL-XppTi7ltf3Wn1hTVhPD9wL7pA7BiFRCgVeKVxROsAXiimHCSztuMN_X2bYvc1Uz-rNjSjMcEuGjfThHCIV3iYrwDCkxCLEtUiUCPv_hDJ_L5b8JWOaAtHJE_J4QJD0qF_5U7IR4jPyqO8pefecxCP69QZCE_1EB87PCR2jlVE8cqXH3-lV-62D5xSPj2sKuLGd4qVI-JXa0nezOzqmeKA_p22kFy0eOdCPXexm9LytY4DhxIg-wRKabXJ5cjz-cJoPTRVyD-BskTd1JbRRTleNhu2IdIKJYGRThNILBoPBFyWS6jjDvALAUGnskhuU4SGBnR2yGbsYXhAKvu-ZK3htHCbztGl8kJ41whtViUplpFgK2PqBcRwbX0xsynyPtO2VYkEpNinFwjdvV99Me76Nv85-j3pbzUSu7PQCLMgOFmT_ZUEZ2Vtq3Q4OPLeYn1UK98sZ2V8Ng-uh-KsYuts0RwF-FGKUkd3eSFYr4bBPw5xtRtSa-awtdX0ktjeJ3lsa8BDNMvJuaWg_l_WwKF7-D1G8IlscPQQLOs0e2VzMbsNrAF0L9yb51w9EpyHC
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED-NISReEN8EBjISbxBIUju2HxAasGl8iocW7c2KHYdFqpKSdmj977lzkqJC2VOq2JZc313uZ9_5dwDPXOYTbcsy5lK4GD2-iJW2eVyi70yrkk-yQF_85Wt-MuMfT8XpHozljoYFXO7c2lE9qVk3f3nxc_0GDf51f2VcvVqiE6KLYinKXAjKL7wCV0O8iFL5Brjfc31nmqd6uDuze-iWfwo0_ruw578plH_FUYN7Or4JNwZcyQ57RbgFe765Ddf6SpPrO9Acsm9n6LDYBzYwgc7ZlHSP0UEsO7pg3-tfLT4XdKhcMkST9YKuSuKvUKy-7dZsyuiYf8nqhn2u6SCCvW-btmOf6rLx2Bx40ueUWHMXZsdH03cn8VBqIXYI2VZxVRZcaWlVUSncpAjLE-61qFKfO55go3dpTlQ7VidOIowoFNXO9VJnPkCge7DftI1_AAy_CC6xaVZqSyE-pSvnhUsq7rQseCEjSMcFNm7gIadyGHMT4uETZXqhGBSKCUIxOOb5ZsyiZ-G4tPdbktumJzFohxdt98MMBmkymyDUElzi157bNLeIW2UiLQVGlc1sBAej1M2olYaitlLSLjqCp5tmNEha_qLx7XnoIxFVcj6J4H6vJJuZZLh7o0huBHJLfbamut3S1GeB9FtotBuVRPBiVLQ_0_r_Ujy8_F88gusZ6T4lcOoD2F915_4xgqyVfRIs5zcnDh6m
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTki8IL4JDGQk3iAiSe3YfiywaZQPIdGhvVmx47BIVVK13bT999w5H6gwkHhqVNuS5bvz_Xx3_hngpct8om1ZxlwKF6PHF7HSNo9L9J1pVfJpFuiLP3_Jj0_4_FSc7kE23IUJRfuB0jJs00N12JsNOhq6DJaiXIWgGsIbsK8kbr8T2J_N5t_mY2SFclc81f0NmWSqrhm844UCWf91CPPPQsnfsqXBCR3dgds9emSzbr53Yc839-Bm957k1X1oZuzrGbol9oH1fJ9LtiANYxRuZYeX7Ht90eLvikLHJUPMWK_oQiR-hSfp2_UVWzAK5m9Y3bBPNYUb2Pu2adfsY102HpsDG_qSymcewMnR4eLdcdw_qBA7BGbbuCoLrrS0qqgUHkWE5Qn3WlSpzx1PsNG7NCdCHasTJxEsFIpeyPVSZz4AnYcwadrGPwaGdu8Sm2altpTIU7pyXrik4k7LghcygnRYYON6tnF69GJpQtZ7qkwnFINCMUEoBse8GsesOq6Nf_Z-S3IbexJPdvijXf8wvd6YzCYIqASXuKdzm-YW0alMpKX0p7KZjeBgkLrpjXdjKDcrJZ2VI3gxNqPZ0fIXjW_PQx-J2JHzaQSPOiUZZ5LhGY3ytRHIHfXZmepuS1OfBWpvodE6VBLB60HRfk3r70vx5P-6P4VbGdkClW3qA5hs1-f-GUKrrX3e29JP4pkauw
  priority: 102
  providerName: Springer Nature
Title A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants
URI https://link.springer.com/article/10.1038/s41598-018-25574-7
https://www.ncbi.nlm.nih.gov/pubmed/29743501
https://www.proquest.com/docview/2036771061
https://www.proquest.com/docview/2037056443
https://pubmed.ncbi.nlm.nih.gov/PMC5943280
https://doaj.org/article/2b03555479114b16b575707b43828b2b
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgExIvaHwubFRG4g2iOakd20-oK51GYdMEHepbFDsOi1Qlpe0Q---5c9xO5WMvSRQ7kuO78_18d74j5I1NHdOmLGMuhY1B44tYaZPFJejOpCp5P_Xpi8_Os9NLPp6KaTC4LUNY5XpN9At12Vq0kR-hw0xK3MC8n_-IsWoUeldDCY37ZDcBJIKlG-RUbmws6MXiiQ5nZVhfHS1BX-GZsgTYQwgMRdzSRz5t_7-w5t8hk3_4Tb06OtkjjwKOpIOO8I_JPdc8IQ-6ypI3T0kzoBdXoKDoRxoyf87oBHmNouGVjn7Rb_XPFu5zNCKXFNBjPcejkfDki9O3ixs6oWjWX9K6oZ9rNDzQD23TLuinumwcNPu86DMMpHlGLk9Gk-FpHEorxBYg2iquyoIrLY0qKgWbEmE4406LKnGZ5QwanU0yTK1jNLMSYEOhsFaukzp1HvI8JztN27h9QmEFsMwkaakNuvSUrqwTllXcalnwQkYkWU9wbkPecSx_Mcu9_7uv8o4oORAl90TJ4Zu3m2_mXdaNO3sfI902PTFjtn_RLr7nQQDz1DCAVoJLWN25STIDOFUyadARqkxqInK4pnoexHiZ3zJdRF5vmkEAcfqLxrXXvo8EFMl5PyIvOibZjCSF3Rp6biMit9hna6jbLU195ZN8Cw1yolhE3q0Z7XZY_5-Kl3f_xQF5mCLvY8CmPiQ7q8W1ewWgamV6XnJ6ZHcwGH8dw_14dH7xBd4Os2HPGyrgesbVb9FZITI
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgheEN8EBhgJniBakjp1_DChjXXqaFdNqEN782LH2SJVSWk7oP8cfxt3btKpfOxtT61qp3J857vzffwO4K2JbCB1lvlcxMZHjR_7idQdP0PdGeYZb0cOvvho2Omd8M-n8ekG_GpqYSitspGJTlBnlSEf-TYFzISgC8zHyTefukZRdLVpoZHWrRWyHQcxVhd29O3iB17hZjuH-0jvd1F00B196vl1lwHfoLUy9_Ms5YkUOknzBO3zWPOAWxnnoe0YHuCgNWGHUGa0DIxADZom1DbWChlZp_3xf2_BJicHSgs297rD4y8rLw_F0Xgo62qdoJ1sz1BjUlVbiAwax5QMuaYRXeOAf1m7fydt_hG5dQrx4D7cqy1ZtrtkvQewYcuHcHvZ23LxCMpddnyBKpIdshp7dMxGxO2MXL-s-5N9Lb5X-DkhN3bG0H4tJlScid_OqadYNV2wEaPAwowVJRsU5Ppg-1VZTVm_yEqLww6ZfUypPI_h5Ea2_Qm0yqq0z4ChDDKBDqNMagoqJjI3NjZBzo0UKU-FB2GzwcrUyOfUgGOsXAS-naglURQSRTmiKHzm_eqZyRL349rZe0S31UzC7HY_VNNzVYsAFekAjbuYC9QvXIcdjZayCISmUGyiI-3BVkN1VQuSmbpiew_erIZRBND2p6WtLt0cgXYs520Pni6ZZLWSCO-LFDv2QKyxz9pS10fK4sLBjMcST2oSePChYbSrZf1_K55f_xav4U5vdDRQg8Nh_wXcjegcUPqo3ILWfHppX6KJN9ev6nPE4Oymj-5vXjFdKg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJhAviG8yBhgJniBqkjpx_DChjbZa6agq1KG9mdhxtkhV0rUd0H-Rv4o71-lUPva2p1a1Uzm-r5_vzneEvNGRCYTKc5_xWPtg8WM_FSrxc7CdYZGzdmTLF38eJkcn7NNpfLpFfjV3YTCtstGJVlHntUYfeQsDZpzjAaZVuLSIUaf3YXrhYwcpjLQ27TQy12Yh37flxtwlj4FZ_oDj3Hy_3wHav42iXnf88ch3HQd8Dchl4Rd5xlLBVZoVKWD1WLGAGREXoUk0C2DQ6DDBijNKBJqDNc1SbCFruIiMRQLwv7fIDgerDwfBncPucPRl7fHBmBoLhbu5E7TT1hysJ95wC4FZ4xgTIzeso20i8C_k-3cC5x9RXGsce_fJPYdq6cGKDR-QLVM9JLdXfS6Xj0h1QEfnYC5pn7o6pBM6Rs6n6Aam3Z_0a_m9hs8purRzCli2nOJFTfh2hv3F6tmSjikGGea0rOhxiW4Q2qmrekYHZV4ZGLZV2ieY1vOYnNzItj8h21VdmWeEgj7SgQqjXCgMMKai0CbWQcG04BnLuEfCZoOldlXQsRnHRNpofDuVK6JIIIq0RJHwzLv1M9NVDZBrZx8i3dYzsX63_aGenUmnDmSkAgB6MeNga5gKEwWomQdcYVg2VZHyyF5DdemUylxeiYBHXq-HQR3g9meVqS_tHA6YlrG2R56umGS9kgjOjhhH9gjfYJ-NpW6OVOW5LTkeC5DaNPDI-4bRrpb1_63Yvf4tXpE7IMLyuD8cPCd3IxQDzCQVe2R7Mbs0LwDtLdRLJ0aUfLtpyf0NNLthbg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Phase+I+Clinical+Trial+with+Ex+Vivo+Expanded+Recipient+Regulatory+T+cells+in+Living+Donor+Kidney+Transplants&rft.jtitle=Scientific+reports&rft.au=Mathew%2C+James+M&rft.au=H-Voss%2C+Jessica&rft.au=LeFever%2C+Ann&rft.au=Konieczna%2C+Iwona&rft.date=2018-05-09&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=8&rft.spage=1&rft.epage=12&rft_id=info:doi/10.1038%2Fs41598-018-25574-7&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon